Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation

Table 2

Univariate and multivariate Cox proportional hazards regression analysis for OS and PFS.

Item	OS	PFS	LRFS	RRFS	DMFS
	Univariate analysis
Age (<80.5 y vs. ≥80.5 y)	0.235	0.743	0.566	0.363	0.876
Gender (male vs. female)	0.030	0.202	0.375	0.232	0.126
KPS (<87.5 vs. ≥87.5)	0.985	0.798	0.272	0.938	0.853
Histology (adenocarchnoma vs. squamous cell vs. others)	0.470	0.528	0.342	0.564	0.941
Dose regimen (<19 f vs. ≥19 f)	0.022	0.025	0.322	0.775	0.015
Location (central vs. peripheral)	0.246	0.401	0.162	0.492	0.438
Chemotherapy (yes vs. no)	0.302	0.172	0.664	0.016	0.060
TNM stage (IIIa vs. IIIb)	0.953	0.428	0.272	0.979	0.806
T stage (T1-2 vs. T3-4)	0.676	0.725	0.436	0.478	0.992
N stage (N0-2 vs. N3)	0.845	0.436	0.433	0.832	0.661
Molecular targeted therapy	0.865	0.271	0.145	0.042	0.699
Multivariate analysis (Cox)
Gender (male vs. female)	0.033	0.155	0.984	0.714	0.108
Molecular targeted therapy	0.882	0.075	0.124	0.143	0.139
Chemotherapy (yes vs. no)	0.706	0.191	0.862	0.357	0.099
Dose fraction (<19 f vs. ≥19 f)	0.020	0.022	0.985	0.667	0.014

OS: overall survival; PFS: progression-free survival; LRFS: local recurrence-free survival; RRFS: regional recurrence-free survival; DMFS: distant metastasis-free survival.